DNY59 Viatris ( NASDAQ: VTRS ) has obtained an exclusive license to market Lexicon Pharmaceuticals’ ( NASDAQ: LXRX ) drug sotagliflozin outside of the United States and Europe for all indications. Under the agreement, Lexicon will receive an upfront payment of $25M, with the potential for milestone payments plus tiered.
Back to Health Page
